Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The triglyceride-glucose index and contrast-induced nephropathy in non-ST elevation myocardial infarction patients undergoing percutaneous coronary intervention.

Tytuł:
The triglyceride-glucose index and contrast-induced nephropathy in non-ST elevation myocardial infarction patients undergoing percutaneous coronary intervention.
Autorzy:
Gursoy E; Koc University Hospital, Department of Cardiology, Istanbul, Turkey.
Baydar O
Źródło:
Medicine [Medicine (Baltimore)] 2023 Jan 13; Vol. 102 (2), pp. e32629.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
MeSH Terms:
Percutaneous Coronary Intervention*/adverse effects
Non-ST Elevated Myocardial Infarction*/surgery
Non-ST Elevated Myocardial Infarction*/etiology
Kidney Diseases*/diagnosis
Humans ; Male ; Female ; Glucose ; Triglycerides ; Retrospective Studies ; Contrast Media/adverse effects ; Risk Factors ; Risk Assessment
References:
Biomed Res Int. 2014;2014:578974. (PMID: 24678510)
Cardiovasc Diabetol. 2014 Oct 20;13:146. (PMID: 25326814)
Front Endocrinol (Lausanne). 2022 Feb 22;13:817176. (PMID: 35273567)
Am J Physiol Renal Physiol. 2001 Jan;280(1):F61-70. (PMID: 11133515)
World J Nephrol. 2017 May 6;6(3):86-99. (PMID: 28540198)
Nat Rev Nephrol. 2016 Dec;12(12):721-737. (PMID: 27748389)
Scand J Clin Lab Invest. 1986 May;46(3):201-6. (PMID: 3715374)
JAMA. 2001 May 16;285(19):2486-97. (PMID: 11368702)
Eur J Radiol. 2006 Dec;60(3):307-13. (PMID: 16965884)
Angiology. 2019 Aug;70(7):627-632. (PMID: 30712366)
Int J Cardiovasc Imaging. 2020 May;36(5):789-796. (PMID: 31919706)
Lancet. 2003 Jan 4;361(9351):13-20. (PMID: 12517460)
J Clin Endocrinol Metab. 2006 Aug;91(8):2906-12. (PMID: 16735483)
Scand J Clin Lab Invest. 1971 Sep;28(1):91-100. (PMID: 5093523)
Am Heart J. 2003 Oct;146(4):674-8. (PMID: 14564322)
Radiology. 2005 Jun;235(3):843-9. (PMID: 15845795)
Metab Syndr Relat Disord. 2008 Dec;6(4):299-304. (PMID: 19067533)
Cardiovasc Diabetol. 2018 Mar 21;17(1):41. (PMID: 29562908)
JACC Cardiovasc Interv. 2014 Jan;7(1):1-9. (PMID: 24456715)
Angiology. 2016 Feb;67(2):139-45. (PMID: 25843952)
Cardiovasc Diabetol. 2019 Nov 13;18(1):150. (PMID: 31722708)
Angiology. 2017 May;68(5):389-413. (PMID: 27485363)
Diabetes Care. 2019 Aug;42(8):1569-1573. (PMID: 31182490)
Circulation. 2004 Oct 19;110(16):2494-7. (PMID: 15477412)
J Am Soc Nephrol. 2000 Jan;11(1):177-182. (PMID: 10616853)
J Am Coll Cardiol. 2004 Nov 2;44(9):1780-5. (PMID: 15519007)
Ann Epidemiol. 2004 Oct;14(9):686-95. (PMID: 15380800)
Diabetes Res Clin Pract. 2011 Sep;93(3):e98-e100. (PMID: 21665314)
J Cardiol. 2009 Apr;53(2):272-7. (PMID: 19304133)
Int J Cardiol. 2013 Apr 5;164(2):141-50. (PMID: 22305775)
Circulation. 2006 Apr 11;113(14):1799-806. (PMID: 16606801)
Diabetes Res Clin Pract. 2018 Sep;143:43-49. (PMID: 29936253)
Nutrients. 2019 Nov 19;11(11):. (PMID: 31752391)
Nephrol Dial Transplant. 2016 Feb;31(2):206-13. (PMID: 25550448)
Eur J Clin Invest. 2016 Feb;46(2):189-97. (PMID: 26683265)
Diabetol Metab Syndr. 2018 Oct 05;10:74. (PMID: 30323862)
J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51. (PMID: 20484475)
Nat Clin Pract Endocrinol Metab. 2008 Aug;4(8):444-52. (PMID: 18607402)
Substance Nomenclature:
IY9XDZ35W2 (Glucose)
0 (Triglycerides)
0 (Contrast Media)
Entry Date(s):
Date Created: 20230113 Date Completed: 20230117 Latest Revision: 20230118
Update Code:
20240105
PubMed Central ID:
PMC9839251
DOI:
10.1097/MD.0000000000032629
PMID:
36637929
Czasopismo naukowe
The triglyceride glucose (TyG) index is an indicator of insulin resistance and associated with increased risk of diabetes mellitus and cardiovascular events. Our study investigates the correlation between TyG index and contrast induced nephropathy (CIN) in non-diabetic patients with non-ST elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI). 350 non-diabetic NSTEMI patients (183, 52.3% male) undergoing PCI were retrospectively enrolled. The enrolled cohort was divided into 2 groups based on the calculated TyG index, namely values < 8.65 or higher. CIN was defined as an increase in serum creatinine > 25% or 0.5 mg/dL from baseline in the first 48 to 72 hours after PCI. A total of 56 (16%) cases of CIN were diagnosed. In contrast to patients with lower TyG indexes, patients with higher TyG indexes (≥8.65) had a higher frequency of CIN, 9.5%. versus 20.8% respectively (P .004). Patients with CIN also had higher TyG indexes (8.74 ± 0.12 vs 8.67 ± 0.11, P < .001). In addition, TyG index, age, and glomerular filtration rate were identified as independent risk factors for CIN in logistic regression model (OR: 2.5 CI: 1.3-4.6, P .006, OR: 1.0 CI: 1.0-1.1, P < .001, OR: 1.0 KI: 1.03-1.06, P .025). In the ROC analysis, the area under the curve predictive of CIN was 0.666 (P < .001, 95% [CI] 0.58-0.75) with a cutoff value of 8.69 (sensitivity 71,4%, specificity 55.1%) TyG index. Higher TyG indexes are associated with an increased risk of CIN in non-diabetic patients with NSTEMI.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies